Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
158
resultados
Última actualización
04/10/2026 [07:44:00]
Resultados 75 a 100 de 158
Resumen de: US20260256860A1
A traditional Chinese medicine composition for treating amyotrophic lateral sclerosis and the use thereof. The composition is prepared by means of combining Ginseng radix et rhizoma and Cistanches herba.
Resumen de: WO2026183114A2
The present disclosure provides, among other things, methods for restoring neuronal function in a subject in need thereof, methods for treating a subject with Alzheimer's Disease (AD) or a subject that has suffered from an acute central nervous system (CNS) injury, and methods for improving one or more brain functions in a subject in need thereof. Such methods can comprise administering to the subject one or more peptide inhibitors of Ca2+/calmodulin-dependent protein kinase II (CaMKII).
Resumen de: US20260256889A1
0000 Disclosed herein is a liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist and a cyclodextrin comprising hydroxypropyl substitutions. Said co-formulation may be used for the medical treatment of subjects with overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated comorbidities; cardiovascular diseases, non-alcoholic steatohepatitis (NASH) and cognitive impairment, such as that caused by Alzheimer's disease.
Resumen de: US20260256745A1
0000 Fenbendazole offers a cure for Diabetes. The glucose levels in diabetes can be normalized by clearing tau and microtubules, resulting in clearing of Hyperglycemia. Hyperglycemia refers to high blood glucose readings, taken from the blood vessels. The glucose is having difficulty passing into some cells through thick microtubules. As seen in recent High Resolution Microscopy: hundreds or thousands of microtubules can be found in a single problematic cell. “during diabetes, microtubules are much denser inside beta cells.” By clearing excess tau oligomers and microtubules, Fenbendazole normalizes the glucose levels. Parkinson's disease also has Hyperglycemia and excess tau oligomers. “tau aggregation correlates with motor deficits and degeneration of dopamine-producing regions of the brain” in Parkinson's. Retinal manifestations of Tau or Amyloid are a biomarker. From the eyes, Tau has been known to proliferate through nerve cells, reaching the brain.
Resumen de: US20260256960A1
Novel lysosomal acid lipase (LAL) positron emission tomography ligands are provided. Also disclosed herein are methods of assessing the risk of developing Alzheimer's disease (AD) or Alzheimer's Disease Related Dementias (ADRD) and methods of diagnosing AD/ADRD in a subject comprising measuring levels of LAL and optionally LAL accumulation in the subject. Methods of treatment comprising administering LAL are also provided.
Resumen de: US20250127867A1
The application describes a phosphorylated tau targeted active immunotherapy to treat preclinical Alzheimer's Disease.
Resumen de: EP4799693A2
The present invention provides methods for treating OFF episodes in a Parkinson's Disease patient comprising administering levodopa to the pulmonary system of a patient wherein after administration, the patient's Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 score is improved by, for example, at least about 5 points compared to placebo control and/or as compared to the patient's UDPRS Part 3 score prior to administration. The invention also provides methods of reducing mean daily OFF time in a Parkinson's patient.
Resumen de: WO2025089370A1
Disclosed are pyrazolopyridine or pyrazolopyrimidine compounds, or salts thereof, with colony-stimulating factor-1 receptor (CSF1R) inhibitory activity, medical use thereof for treating, preventing, and/or diagnosing diseases associated with CSF1R, and methods of preparing said compounds, or salts thereof. Provided include a compound represented by Formula I, or a salt thereof, wherein R1 is hydrogen, etc.; R21 and R22 are hydrogen, or R21 and R22 together with the adjacent heterocyclic form a bridged bicyclic ring; R3 is -L31-R31 optionally substituted with one or more R32, or R31 optionally substituted with one or more R32; L31 is -C(=O)-, etc.; R31 is C1-6 alkyl, etc.; R32 is each independently halogen, etc.; and X is CR1 or N; medical use thereof, and methods of preparation thereof.
Resumen de: WO2025087971A1
The invention relates to the treatment of Alzheimer's disease in a human patient, said treatment comprising administration of an anti-Aβ antibody component and co-administration of edaravone, the anti-Aβ antibody component being selected from anti-Aβ antibody, an Aβ- binding fragment of an Aβ antibody, a vectorised anti-Aβ antibody and a vectorised Aβ- binding fragment of an Aβ antibody.
Resumen de: WO2025163129A1
The present disclosure provides for treating Parkinson´s disease (PD) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof to a subject in need thereof.
Resumen de: WO2025154076A1
This invention provides a method of prolonging the survival of subjects afflicted with ALS by administering a composition comprising pridopidine or pharmaceutically acceptable salt thereof.
Resumen de: US20260248883A1
0000 Disclosed is a pharmaceutical composition for preventing or treating a brain disease, containing as an active ingredient an ErbB3-binding protein 1 (EBP1) protein or a polynucleotide sequence encoding the EBP1 protein, wherein an EBP1 N84A/N204A protein, which is an EBP1 mutant in an asparagine endopeptidase (AEP)-uncleavable form, and a polynucleotide encoding the same can reduce amyloid beta production and enhance cognitive function in the early stages of Alzheimer's disease, and thus the composition can be advantageously used as a therapeutic agent for brain diseases including sporadic Alzheimer's disease.
Resumen de: US20260250396A1
Provided herein are therapies involving the use of antibodies that bind to Gal-3. Such therapies can include, but are not limited to, disorders such as Alzheimer's disease. Such therapies can also include treatments focused on increasing a subject's test scores under a variety of metrics.
Resumen de: US20260250256A1
0000 Disclosed are compounds of Formulas (I), (Ia), (Ib), (II), (IIa), (III), (IIIa), and (IIIb), as well as pharmaceutical compositions thereof. The compounds can be used to improve proteostasis and enhance clearance of protein accumulation events by positively modulating the autophagy-lysosomal pathway, including augmenting the activity of cathepsin enzymes, and/or to treat neurological diseases, disorders and conditions, such as, but not limited to, Alzheimer's disease, Parkinson's disease, Huntington's disease, mild cognitive impairment, frontotemporal dementia, amyotrophic lateral sclerosis, Lewy body dementias, chronic traumatic encephalopathy, traumatic brain injury, and α-synucleinopathies.
Resumen de: WO2026178437A2
The present invention relates to methods for treating, preventing or delaying onset, and alleviating the symptoms of amyotrophic lateral sclerosis (ALS) through nasally or intrathecally administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising dantrolene or a combination of dantrolene and a lithium salt, and a pharmaceutically acceptable carrier. The present invention further relates to methods for treating depression comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising dantrolene or a combination of dantrolene and a lithium salt, and a pharmaceutically acceptable carrier. The present invention additionally relates to methods for treating depression in an Alzheimer's Disease subject comprising administering a pharmaceutical composition comprising dantrolene or a combination of dantrolene and a lithium salt, and a pharmaceutically acceptable carrier.
Resumen de: US20260248877A1
0000 The present invention provides inhibitory peptides for use in the diagnostic and/or treatment of tauopathies, in particular Alzheimer's Disease and Pick's Disease. The inhibitory peptides comprise a hexapeptide sequence that specifically inhibits interactions of the PHF6 sequence within pathological Tau protein.
Resumen de: WO2026178556A1
Among other things, the present disclosure provides oligonucleotides, compositions, and methods useful for targeting HTT. In some embodiments, provided oligonucleotides comprise nucleobase modifications, sugar modifications, internucleotidic linkage modifications and/or patterns thereof, and have improved properties and activities. In some embodiments, the present disclosure provides oligonucleotides, compositions and methods for reducing HTT levels. In some embodiments, the present disclosure provides oligonucleotides, compositions and methods for treating conditions, disorders or diseases such as Huntington's disease.
Resumen de: US20260248941A1
0000 Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a microtubule associated protein tau (MAPT) gene. The MAPT RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a MAPT gene. The MAPT RNAi agents are conjugated to an antigen binding protein that may enable subcutaneous delivery of the RNAi agents by facilitating crossing of the blood brain barrier (BBB). Pharmaceutical compositions that include one or more MAPT RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MAPT RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of MAPT gene expression and a reduction in MAPT activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including Alzheimer's disease, Frontotemporal lobar degeneration dementia (FTLD), Progressive supranuclear palsy, and other tauopathies.
Resumen de: US20260250715A1
The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof, Lysosomal Membrane Protein 2 (LIMP2), Prosaposin, or any combination of the foregoing. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.
Resumen de: US20260248855A1
Use of a transforming growth factor beta 1 (TGF-β1)-overexpressing olfactory mucosa mesenchymal stem cell (OM-MSC) in preparation of a drug for preventing and/or treating Parkinson's disease (PD) is provided, belonging to the technical field of drug preparation. The TGF-β1-overexpressing OM-MSCs can be used to better conduct a neural repair treatment of the PD. By verifying effects of the TGF-β1-overexpressing OM-MSCs in a PD cell model and a PD animal model, it is proved that the TGF-β1-overexpressing OM-MSCs do have a therapeutic effect on PD.
Resumen de: WO2025085704A1
This disclosure relates to vectors, compositions, pharmaceutical compositions, and kits that provide for brain cell-specific expression of reprogramming genes such as the Yamanaka factors Oct4, Sox2, Klf4 and c-Myc (OSKM). Also provided are methods and uses comprising the same for treating Alzheimer' s disease and progeria through brain cell-specific expression of reprogramming genes such as OSKM.
Resumen de: WO2025083630A1
The present invention relates to heteroaromatic compounds of formula (I), or an isotopic form, a stereoisomer, or a pharmaceutically acceptable salt thereof as muscarinic M4 receptor positive allosteric modulators (M4 PAMs). The present invention also relates to pharmaceutical compositions comprising such compounds, chemical processes of preparation of such compounds and use of such compounds in the treatment of psychiatric and/or neurological disorders.
Resumen de: EP4796178A2
Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative diseases, such as Huntington's Disease (HD).
Resumen de: WO2026174035A1
Disclosed are N-terminal modified peptides, and their use in the treatment of diseases such as diabetes, obesity, Alzheimer's disease, liver disease, substance addiction, traumatic brain injury, chronic kidney disease, inflammation and cardiovascular diseases.
Nº publicación: WO2026171281A1 20/08/2026
Solicitante:
RACTIGEN THERAPEUTICS [CN]
RACTIGEN THERAPEUTICS
Resumen de: WO2026171281A1
Provided are MAPT-targeting siRNAs for preventing or treating neurological diseases or conditions, such as those associated with abnormal MAPT expression or tauopathies, and a range of neurodegenerative disorders including Alzheimer's disease.
BOPI
Sede Electrónica
